Vanguard Group Inc Summit Therapeutics Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,946,536 shares of SMMT stock, worth $202 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,946,536
Previous 8,818,463
24.13%
Holding current value
$202 Million
Previous $68.8 Million
248.52%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SMMT
# of Institutions
193Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$452 Million5.73% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$146 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$101 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$64.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$57.3 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.72B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...